Journal article
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas
British journal of cancer, Vol.125(4), pp.528-533
08/2021
DOI: 10.1038/s41416-021-01448-0
PMCID: PMC8368095
PMID: 34050255
Abstract
Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patients with sarcoma.
This prospective, single arm, phase II study evaluated the efficacy of the combination of pazopanib with topotecan in patients with metastatic or unresectable non-adipocytic STS. Furthermore, it incorporated exploratory arms for osteosarcoma and liposarcoma. The primary endpoint was progression-free rate at 12 weeks in the non-adipocytic STS cohort.
57.5% of patients in the non-adipocytic STS cohort were progression free at 12 weeks, which did not meet the primary endpoint of the study (66%). The exploratory osteosarcoma cohort exceeded previously established phase II trial comparator data benchmark of 12% with a PFR at 12 weeks of 69.55%. Treatment with the combination of pazopanib and topotecan was accompanied by a grade 3 or 4 toxicities in most patients.
In this prospective trial in refractory metastatic or unresectable STS and osteosarcoma, the combination of pazopanib with topotecan did not meet its primary endpoint of progression-free rate at 12 weeks. The combination of pazopanib with topotecan was associated with a high degree of toxicity.
Details
- Title: Subtitle
- Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas
- Creators
- Brian Schulte - Northwestern UniversityNisha Mohindra - Northwestern UniversityMohammed Milhem - University of IowaSteven Attia - Mayo Clinic in FloridaSteven Robinson - Mayo ClinicVarun Monga - University of IowaAngela C Hirbe - Washington University in St. LouisPeter Oppelt - Washington University in St. LouisJohn Charlson - Medical College of WisconsinIrene Helenowski - Northwestern UniversitySusan Abbinanti - Northwestern UniversityRasima Cehic - Northwestern UniversityScott Okuno - Mayo ClinicBrian A Van Tine - Washington University in St. LouisMark Agulnik - Northwestern University
- Resource Type
- Journal article
- Publication Details
- British journal of cancer, Vol.125(4), pp.528-533
- DOI
- 10.1038/s41416-021-01448-0
- PMID
- 34050255
- PMCID
- PMC8368095
- ISSN
- 0007-0920
- eISSN
- 1532-1827
- Grant note
- P30 CA015083 / NCI NIH HHS
- Language
- English
- Date published
- 08/2021
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359577902771
Metrics
7 Record Views